PolyMedix, Inc. – Product Pipeline Review – H2 2011

Date: November 1, 2011
Pages: 77
Price:
US$ 500.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P1C2FE10658EN
Leaflet:

Download PDF Leaflet

PolyMedix, Inc. – Product Pipeline Review – H2 2011
PolyMedix, Inc. – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “PolyMedix, Inc. - Product Pipeline Review - H2 2011” provides data on the PolyMedix, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, PolyMedix, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from PolyMedix, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • PolyMedix, Inc. - Brief PolyMedix, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of PolyMedix, Inc. human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of PolyMedix, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the PolyMedix, Inc.’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate PolyMedix, Inc.’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of PolyMedix, Inc. in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the PolyMedix, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with PolyMedix, Inc..
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of PolyMedix, Inc. and identify potential opportunities in those areas.
PolyMedix, Inc. Snapshot
PolyMedix, Inc. Overview
Key Information
Key Facts
PolyMedix, Inc. – Research and Development Overview
Key Therapeutic Areas
PolyMedix, Inc. – Pipeline Review
Pipeline Products by Stage of Development
PolyMedix, Inc. – Pipeline Products Glance
PolyMedix, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
PolyMedix, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
PolyMedix, Inc. – Drug Profiles
PMX-10070
  Product Description
  Mechanism of Action
  R&D Progress
PMX-10072
  Product Description
  Mechanism of Action
  R&D Progress
PMX-10098
  Product Description
  Mechanism of Action
  R&D Progress
PMX-20005
  Product Description
  Mechanism of Action
  R&D Progress
PMX-30016
  Product Description
  Mechanism of Action
  R&D Progress
PMX-30024
  Product Description
  Mechanism of Action
  R&D Progress
PMX-30063
  Product Description
  Mechanism of Action
  R&D Progress
PMX-60056
  Product Description
  Mechanism of Action
  R&D Progress
PMX-70004
  Product Description
  Mechanism of Action
  R&D Progress
PMX-70008
  Product Description
  Mechanism of Action
  R&D Progress
PolyMedix, Inc. – Pipeline Analysis
PolyMedix, Inc. – Pipeline Products by Therapeutic Class
PolyMedix, Inc. - Pipeline Products By Target
PolyMedix, Inc. – Pipeline Products by Route of Administration
PolyMedix, Inc. – Pipeline Products by Molecule Type
PolyMedix, Inc. – Recent Pipeline Updates
PolyMedix, Inc. - Dormant Projects
PolyMedix, Inc. – Company Statement
PolyMedix, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Mar 31, 2010: PolyMedix Completes Phase IB Clinical Study With Antibiotic PMX-30063
Sep 28, 2010: PolyMedix Initiates Phase II Clinical Trial With PMX-30063 Against Bacterial Infections
Apr 28, 2011: PolyMedix Announces Defensin-Mimetic Antibiotic PMX-30063 Active Against NDM-1 Drug-Resistant Bacteria
Apr 28, 2010: PolyMedix Initiates Phase IB/2 Dose-Ranging Clinical Study With PMX-60056
Oct 27, 2009: PolyMedix Completes Successful Phase IB Clinical Study of Heparin Antagonist PMX-60056
Sep 27, 2011: PolyMedix Initiates Phase IB/II Dose-Response Clinical Trial To Reverse Anticoagulant Activity Of Enoxaparin With PMX-60056
Oct 24, 2011: PolyMedix Presents PMX-30063 Antibiotic Data At Infectious Disease Society of America And HIV Medicine Association
Aug 24, 2008: PMX-30063 The First And Only Defensin Mimetic Systemic Antibiotic Drug In Human Clinical Trials
Feb 24, 2011: PolyMedix Successfully Completes Phase I Exposure Escalation Safety Study With PMX-30063 Antibiotic
Oct 21, 2010: PolyMedix Provides Updates On PMX-60056 Heptagonist Program
Sep 19, 2011: PolyMedix Presents Antibiotic Data At 51st Interscience Conference on Antimicrobial Agents And Chemotherapy
May 19, 2011: PolyMedix's PMX-30063 Defensin-Mimetic Antibiotic Compound Shows Promising Activity For Oral Mucositis
Dec 18, 2009: PolyMedix Completes Phase IB Clinical Trial Study Of PMX 30063 For The Treatment Of Staphylococcus Aureus
Mar 18, 2010: PolyMedix Initiates Phase IB Clinical Study With PMX-60056 To Reverse Low Molecular Weight Heparin
Nov 15, 2010: PolyMedix Presents PMX-60056 Clinical Data At American Heart Association Scientific Sessions Meeting
May 12, 2011: PolyMedix Presents Clinical And Preclinical Data On PMX-30063 Defensin-Mimetic Antibiotic At ECCMID 2011 Meeting
Mar 12, 2010: PolyMedix Presents PMX-30063 Antibiotic Phase IB Clinical Data At 8th World Congress On Trauma, Shock, Inflammation And Sepsis
Dec 11, 2008: PolyMedix Announces Positive Phase I Clinical Data With PMX-30063 Novel Antibiotic Drug Candidate
Aug 11, 2010: PolyMedix Successfully Completes Phase IB/II Heparin Dose-Ranging Study With PMX-60056 Heptagonist
Nov 10, 2010: PolyMedix Obtains Regulatory Clearance For US IND Application For PMX-30063 Antibiotic
Feb 09, 2011: PolyMedix Initiates Phase II Clinical Trial With PMX-60056
Sep 08, 2010: PolyMedix To Present Antibiotic Data At 50th Interscience Conference On Antimicrobial Agents and Chemotherapy
Dec 07, 2010: PolyMedix Presents PMX-60056 Phase Ib/II Data At American Society Of Hematology Meeting
May 05, 2011: PolyMedix Announces Presentation Of Four Abstracts At ECCMID 2011 Meeting
Nov 04, 2010: PolyMedix Announces Two Presentations On PMX-60056 At American Heart Association Meeting
Jun 03, 2010: PolyMedix Successfully Completes Phase IB Clinical Study To Reverse Low Molecular Weight Heparin With PMX-60056
May 03, 2011: PolyMedix Presents Data On PMX-60056 At American Heart Association ATVB-2011 Meeting
Financial Deals Landscape
PolyMedix, Inc., Deals Summary
PolyMedix, Inc., Pharmaceuticals & Healthcare, Deal Details
Venture Financing
PolyMedix Secures Additional $4 Million In Series B Financing
PolyMedix Secures $2 Million In The First Tranche Of Series B Financing
Licensing Agreements
PolyMedix Enters Into Licensing Agreement With University of Massachusetts
Equity Offering
PolyMedix Completes Public Offering Of $20 Million
PolyMedix Completes Registered Public Offering Of Units For $20.7 Million
PolyMedix Enters Into Agreement With Dutchess Equity For $10 Million
PolyMedix Completes Private Placement Of $4.25 Million
PolyMedix Closes $15 Million Registered Equity Financing
PolyMedix Completes Private Placement Of Units For $3.24 Million
PolyMedix Raises $21 Million In Equity Financing
Acquisition
BTHC II Acquisition Acquires PolyMedix In Reverse Acquisition
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

PolyMedix, Inc. – Pipeline by Therapy Area and Indication, H2 2011
PolyMedix, Inc. – Pipeline by Stage of Development, H2 2011
PolyMedix, Inc. - Phase II, H2 2011
PolyMedix, Inc. - Pipeline By Therapeutic Class, H2 2011
PolyMedix, Inc. - Pipeline By Target, H2 2011
PolyMedix, Inc. – Pipeline By Route of Administration, H2 2011
PolyMedix, Inc. – Pipeline By Molecule Type, H2 2011
PolyMedix, Inc. – Recent Pipeline Updates, H2 2011
PolyMedix, Inc. - Dormant Developmental Projects, 2010
PolyMedix, Inc., Subsidiaries
PolyMedix, Inc., Deals Summary
PolyMedix Secures Additional $4 Million In Series B Financing
PolyMedix Secures $2 Million In The First Tranche Of Series B Financing
PolyMedix Enters Into Licensing Agreement With University of Massachusetts
PolyMedix Completes Public Offering Of $20 Million
PolyMedix Completes Registered Public Offering Of Units For $20.7 Million
PolyMedix Enters Into Agreement With Dutchess Equity For $10 Million
PolyMedix Completes Private Placement Of $4.25 Million
PolyMedix Closes $15 Million Registered Equity Financing
PolyMedix Completes Private Placement Of Units For $3.24 Million
PolyMedix Raises $21 Million In Equity Financing
BTHC II Acquisition Acquires PolyMedix In Reverse Acquisition

LIST OF FIGURES

PolyMedix, Inc. – Pipeline by Therapy Area and Indication, H2 2011
PolyMedix, Inc. – Pipeline by Stage of Development, H2 2011
PolyMedix, Inc. – Pipeline By Therapeutic Class, H2 2011
PolyMedix, Inc. - Pipeline By Target, H2 2011
PolyMedix, Inc. – Pipeline By Route of Administration, H2 2011
PolyMedix, Inc. – Pipeline By Molecule Type, H2 2011

Ask Your Question

PolyMedix, Inc. – Product Pipeline Review – H2 2011
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: